EyePoint Pharmaceuticals, Inc.: DURAVYU Phase 3 Trials Enrollment Completed for Wet Age-Related Macular Degeneration Treatment

EyePoint Pharmaceuticals, Inc. has successfully completed the enrollment of its Phase 3 pivotal program for DURAVYU in the treatment of wet age-related macular degeneration (wet AMD). The LUCIA trial, the second of two identical pivotal non-inferiority trials, enrolled and randomized over 400 patients in just seven months, showcasing the strong interest in the DURAVYU program within the global retinal community. Supported by robust safety and efficacy data from the DAVIO 2 Phase 2 clinical trial, DURAVYU has demonstrated a favorable safety profile across multiple clinical trials. The completion of enrollment for both LUGANO and LUCIA trials marks a significant milestone for EyePoint Pharmaceuticals as they move closer to bringing a sustained-release TKI for wet AMD to market. Anticipated topline data for the LUGANO trial is expected in mid-2026, with results from the LUCIA trial to follow shortly after.